Halozyme Therapeutics, Inc.
0J2O.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.32B
Close$
$236.81
117.6% upside
Current Fair Value
117.6% upsideUndervalued by 117.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.32 Billion |
|---|---|
| Enterprise Value | $15.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.64 |
| Beta | 0.85 |
| Outstanding Shares | 117,274,000 |
Return
| Return on Equity | 288.13% |
|---|---|
| Return on Assets | 16.05% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | 31.37 |
|---|---|
| PEG | 80.01 |
| Price to Sales | 7.77 |
| Price to Book Ratio | 108.82 |
| Enterprise Value to Revenue | 9.2 |
| Enterprise Value to EBIT | 16.12 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 14.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.79
Average shareholder expectationRevenue Estimate
$402.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$2.28
Average shareholder expectationRevenue Estimate
$487.13 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Halozyme Therapeutics Inc.
423 employees
CEO: Helen Torley Halozyme Therapeutics, Inc., a biopharmaceutical technology company, was established in 1998 and is based in San Diego, California. The company's operations span globally, covering markets in the United States, Switzerland, Ireland, Belg...